Inactive Instrument

Neutra Corp Stock OTC Bulletin Board

US64129C2044

Pharmaceuticals

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

25-03-31	Neutra Corp. executed a letter of intent to acquire CuraConnector.com, Inc.	CI
24-08-07	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI

Neutra Corp. is an early-stage research and development company. The Company is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The Company plans to research and bring new technology to the Nutraceutical space. The Company is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. It intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. It primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	460K 403K 372K 347K 654K 43.5M 669K 4.48M 1.73M 21.46M 1.73M 1.69M 74.51M	P/E 2023	-1.94x	P/E 2024	-3.75x
Enterprise Value	525K 459K 424K 396K 745K 49.6M 762K 5.1M 1.97M 24.47M 1.97M 1.93M 84.96M	EV / Sales 2023	18,402,377x	EV / Sales 2024	23,773,714x
Free-Float	99.31%	Yield 2023 *	-	Yield 2024	-

25-03-31	Neutra Corp. executed a letter of intent to acquire CuraConnector.com, Inc.	CI
24-08-07	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
24-08-02	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2024	CI
23-12-15	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	CI
23-09-14	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	CI
23-06-22	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2023	CI
23-06-09	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2023	CI
23-06-08	Neutra Corp. Auditor Raises 'Going Concern' Doubt	CI
23-01-29	Neutra Corp. executed a binding letter of intent to acquire Mercury Clinical Research, Inc.	CI
22-12-15	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	CI
22-09-14	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	CI
22-06-21	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2022	CI
22-05-10	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2022	CI

01-19	Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year	AQ
25-10-13	Neutra Corp's Subsidiary, Neutra Life Sciences, Adds to Its Site Network With New Joint Venture Partnership in Family Medicine	AQ
25-08-25	Neutra Corp Launches Corporate Rebranding Initiative, Unveils New Logo, New Website, and Strengthens Focus on Life Sciences Through Its SMO	AQ
25-08-04	Neutra Corps Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships	AQ
25-08-04	Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+1.61%	+11.22%	+57.24%	+163.88%	1,077B
JOHNSON & JOHNSON	+1.14%	+11.21%	+68.39%	+56.75%	613B
ABBVIE INC.	+0.50%	+11.07%	+37.63%	+91.75%	448B
ROCHE HOLDING AG	+1.86%	+4.85%	+28.17%	+22.04%	332B
ASTRAZENECA PLC	-0.14%	+7.58%	+41.28%	+27.25%	293B
NOVARTIS AG	-0.06%	+4.92%	+31.23%	+41.59%	286B
NOVO NORDISK A/S	-0.96%	+4.98%	-28.37%	-40.96%	215B
AMGEN INC.	+0.38%	+4.65%	+29.20%	+63.12%	193B
GILEAD SCIENCES, INC.	-1.49%	+0.77%	+13.49%	+65.54%	159B
Average	+0.35%	+8.48%	+30.92%	+54.55%	401.79B
Weighted average by Cap.	+0.83%	+9.65%	+42.18%	+81.14%

	2023	2024
Net sales	0.07 0.06 0.05 0.05 0.1 6.43 0.1 0.66 0.26 3.17 0.26 0.25 11.01	0.04 0.03 0.03 0.03 0.06 3.74 0.06 0.38 0.15 1.84 0.15 0.15 6.4
Net income	-561K -492K -454K -424K -798K -53.08M -816K -5.46M -2.11M -26.19M -2.11M -2.06M -90.91M	-233K -204K -189K -176K -332K -22.07M -339K -2.27M -877K -10.89M -877K -858K -37.81M
Net Debt	54.5K 47.72K 44.05K 41.14K 77.44K 5.15M 79.21K 530K 205K 2.54M 205K 200K 8.83M	64.5K 56.48K 52.14K 48.69K 91.65K 6.1M 93.74K 627K 242K 3.01M 242K 237K 10.45M

Neutra Corp Stock OTC Bulletin Board

Stocks

US64129C2044

Pharmaceuticals

Valuation: Neutra Corp

Latest news : Neutra Corp

Press Releases: Neutra Corp

Managers and Directors: Neutra Corp

Other Pharmaceuticals

Financials

Company Profile